reports
- Daniel Appiah
- John Savin PhD
- Robin Davison
Phase Ia progressing successfully; new COVID strain
The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the development of Nanoviricides' (NV) novel and innovative anti-virus therapy, NV-CoV-2 uses a sophisticated polymer (NV-387) as the active ingredient to trap and disrupt viruses in the blood. The therapy aims to reduce the viral l
- Daniel Appiah
- John Savin PhD
- Robin Davison
COVID-19 therapy trial underway, RSV trial to follow
Nanoviricides (NV) has announced its first clinical study, a key milestone in the development of its novel and innovative anti-virus therapy, NV-CoV-2. The technology uses a sophisticated large polymer (NV-387) to trap and disrupt viruses in the blood. The therapy aims to reduce the viral load to p
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Confe...
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which will be held on May 10-11, 2023, at the Plaza Hotel in the heart of New York City. NanoViricides is pres...
DGAP-News: NanoViricides, Inc. Has Filed its Annual Report: Coronaviru...
DGAP-News: NanoViricides, Inc. / Key word(s): Annual Report NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage 13.10.2021 / 12:45 The issuer is solely responsible for the content of this announcement. NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE Amer.:) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with th...
DGAP-News: NanoViricides, Inc.: Broad-Spectrum Direct Antiviral Nanome...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides, Inc.: Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan 27.01.2021 / 12:15 The issuer is solely responsible for the content of this announcement. Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan SHELTON, CT / ACCESSWIRE / January 27, 2021 / NanoViricides, Inc. (NYSE American: ) (the "Compa...
DGAP-News: NanoViricides Has Filed Quarterly Report for Period Ending ...
DGAP-News: NanoViricides, Inc. / Key word(s): Quarter Results NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress 17.11.2020 / 12:20 The issuer is solely responsible for the content of this announcement. NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress SHELTON, CT / ACCESSWIRE / November 17, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly ...
DGAP-News: NanoViricides to Participate in Panel Discussion at the B. ...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 21.07.2020 / 12:15 The issuer is solely responsible for the content of this announcement. NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 SHELTON, CT / ACCESSWIRE / July 21, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective antiviral therapies based ...
DGAP-News: NanoViricides Closes On $11.5 Million Underwritten Public O...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock 13.07.2020 / 14:00 The issuer is solely responsible for the content of this announcement. NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock SHELTON, CT / ACCESSWIRE / July 13, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underw...
DGAP-News: NanoViricides, Inc. Prices $10.0 Million Underwritten Publi...
DGAP-News: NanoViricides, Inc. / Key word(s): Offer NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock 09.07.2020 / 12:15 The issuer is solely responsible for the content of this announcement. NanoViricides Prices $10.0 Million Underwritten Public Offering of Common Stock SHELTON, CT / ACCESSWIRE / July 09, 2020 / NanoViricides, Inc. (NYSE American: (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), today announced the pricing of an underwritten ...
DGAP-News: NanoViricides Announces Addition to Russell Microcap(R) Ind...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides Announces Addition to Russell Microcap(R) Index 30.06.2020 / 12:15 The issuer is solely responsible for the content of this announcement. NanoViricides Announces Addition to Russell Microcap(R) Index SHELTON, CT / ACCESSWIRE / June 30, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has been added to the Russell Microcap(R) Index effective after the U.S....
DGAP-News: NanoViricides, Inc.: Strong Effectiveness of NanoViricides ...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides, Inc.: Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus 20.05.2020 / 12:15 The issuer is solely responsible for the content of this announcement. Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus SHELTON, CT / ACCESSWIRE / May 20, 2020 / NanoViricides, Inc. (NYSE American: ) (the "Company") a leader in the development of highly effective a...
NanoViricides, Inc. Progress on COVID-19 Drug Encouraging
The Company's Update on its Development of COVID-19 Drug Candidate is PromisingVancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company's research involves the use of a unique nanomedicine technology called nanoviricides -- agents designed to "fool" a virus into attaching to an antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell su...
DGAP-News: NanoViricides, Inc.: Coronavirus Drug Development Update fr...
DGAP-News: NanoViricides, Inc. / Key word(s): Miscellaneous NanoViricides, Inc.: Coronavirus Drug Development Update from NanoViricides, Inc. 16.03.2020 / 11:15 The issuer is solely responsible for the content of this announcement. Coronavirus Drug Development Update from NanoViricides, Inc. Â SHELTON, CONNECTICUT -- March XX, 2020 -- NanoViricides, Inc. (NYSE American: ) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), is providing an update on its efforts towards drug devel...
NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding ...
The Company has been working on a drug candidate to address the COVID-19 and has made significant progress in this regardNew York, New York--(Newsfile Corp. - March 5, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company has recently been in the news for being one of the few biotechnology companies that is actively working on developing a drug that can treat COVID-19, the coronaviral pneumonia disease which is caused by the SARS-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.